AI
Wednesday, September 25, 2024 12:27:11 AM
See how many trials on dendritic cells on clinicaltrials.gov. Over 500, but there is only one DC vaccine can do the following.
As the Company previously reported, proteomic studies have demonstrated that a single tumor lysate sample contained tens of thousands of different peptides and, out of this pool, the dendritic cells selected, processed and presented over 600 different peptides (tumor targets) to T cells. T cell studies (TCR sequencing and T cell clonal expansion assays) analyzing the breadth and strength of T cell response following DCVax-L treatment have found extensive responses, including clonal expansion of up to 800 T cell clones at month 4 and up to 1200 T cell clones at month 8 in the samples studied. Each T cell clone focuses on a particular and distinct target. In individuals not being treated with the vaccine, only 2 – 20 new T cells clones are seen between month 4 and month 8.
The results of these proteomic, T cell and other studies provide support for what the Company believes to be the mechanism of action of DCVax-L: i.e., mobilizing a broad spectrum and strong de novo T cell response that addresses the extensive heterogeneity of GBM and overcomes the immunosuppressive microenvironment around the tumor.
https://clinicaltrials.gov/search?titles=%22dendritic%20cell%22
As a matter of fact, I repeatedly mentioning about this ever since the ASCO presentation. NWBO mentioned about last December. John Hempton blocked me right away when I showed him the data. He was scared, was he not? I bet you are scared too. Before the submission of the application package, you were more or less dormant. Right after the package was filed, your agitation started spiking and you have been agitated ever since. You do know you are in a trap, do you not? So stop digging.
